国家银屑病基金会与国际银屑病理事会联合声明:使用IL-17或IL-23抑制剂治疗银屑病患者无需常规筛查潜伏性结核感染
该联合声明由美国国家银屑病基金会医学委员会与国际银屑病理事会专家制定,基于对IL-17和IL-23抑制剂在潜伏性结核感染背景下安全性的证据回顾,形成并批准了新立场声明。87.5%的成员批准该声明,指出使用IL-17或IL-23抑制剂治疗银屑病患者不需要检测潜伏性结核感染,但合并免疫抑制治疗或居住在结核流行区的患者可考虑例外。
要点
- 使用IL-17或IL-23抑制剂治疗银屑病无需常规检测潜伏性结核感染。
- 合并免疫抑制治疗或居住在结核流行区者可考虑继续检测。
- 该声明由87.5%的专家成员批准。
核心结论
- 银屑病专家达成共识:使用IL-17或IL-23抑制剂治疗银屑病患者不需要常规检测潜伏性结核感染。
研究设计与样本
- 由美国国家银屑病基金会医学委员会和国际银屑病理事会专家回顾IL-17和IL-23抑制剂在潜伏性结核感染背景下的安全性证据,形成并批准联合立场声明。
主要发现
- 87.5%的国家银屑病基金会医学委员会和国际银屑病理事会成员批准了新联合立场声明,指出使用IL-17或IL-23抑制剂治疗银屑病患者不需要检测潜伏性结核感染。
关键数值与推荐
- 声明批准率为87.5%。
- 例外情况包括合并免疫抑制治疗的患者和居住在结核流行区的患者,可考虑继续检测潜伏性结核感染。
临床怎么用
- 临床医生在使用IL-17或IL-23抑制剂治疗银屑病时,无需常规检测潜伏性结核感染;但对合并免疫抑制治疗或居住在结核流行区的患者可考虑检测。
局限性
- 该立场声明允许例外情况,即对于合并免疫抑制治疗或居住在结核流行区的患者,可考虑继续检测潜伏性结核感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak. OBJECTIVES: To review evidence on safety of IL-17 and IL-23 inhibitors in the setting of latent TB infection and to provide a new Joint Position Statement on this topic. METHODS: Experts from the National Psoriasis Foundation and the International Psoriasis Council reviewed evidence regarding progression of latent TB infection to active disease in psoriasis patients receiving IL-17 or IL-23 blockers. A Joint Position Statement was formulated and approved to provide updated guidance to clinicians. RESULTS: 87.5% of the members from the National Psoriasis Foundation Medical Board and International Psoriasis Council approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required. LIMITATIONS: This position statement allows for exceptions where continued testing for late nt TB infection could be considered, including for patients on concomitant immunosuppressive therapy and for those living in TB endemic areas. CONCLUSION: Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.
引用
- Blauvelt A, Strober BE, Eakin GS, et al. Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. J Am Acad Dermatol. 2025. PMID: 41260526. doi:10.1016/j.jaad.2025.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。